CAR-T Meeting 2022 | An overview of T4 immunotherapy
John Maher
• 16 Feb 2022
John Maher, BA, MBBCh, BAO, MRCPI, MRCP, MSc, FRCPath, King’s College London, London, UK, outlines the design and rationale of T4 immunotherapy for patients with relapsed/refractory (R/R) head and neck cancer. T4 immunotherapy is an autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to co-express two chimeric receptors: T1E28z, which targets the ErbB network, and 4αβ, a chimeric cytokine receptor used to select only T-cells that express the CAR. This immunotherapy is currently being evaluated in a Phase I clinical trial (NCT01818323). This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
